ALLMedicine™ Complex Partial Seizures Center

Aug 4th, 2022 - Practice Essentials Hypomelanosis of Ito (HI) syndrome is characterized by the presence of whirled hypochromic skin lesions (see the image below) often associated with systemic manifestations. Hypomelanosis of Ito on the torso. Pathophysiology The...

Aug 4th, 2022 - Practice Essentials Hypomelanosis of Ito (HI) syndrome is characterized by the presence of whirled hypochromic skin lesions (see the image below) often associated with systemic manifestations. Hypomelanosis of Ito on the torso. Pathophysiology The...

Aug 4th, 2022 - Practice Essentials Hypomelanosis of Ito (HI) syndrome is characterized by the presence of whirled hypochromic skin lesions (see the image below) often associated with systemic manifestations. Hypomelanosis of Ito on the torso. Pathophysiology The...

Aug 4th, 2022 - NeuroPace is sponsoring the RESPONSE Study with the RNS System in individuals age 12 through 17 with partial (focal) onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or mo...

Jun 7th, 2022 - Dysembryoplastic neuroepithelial tumors (DNETs) are rare, low-grade tumors of the central nervous system (CNS) of childhood. It is an important cause of intractable epilepsy, and it is surgically curable. We aimed to review our institutional exper...

Aug 4th, 2022 - NeuroPace is sponsoring the RESPONSE Study with the RNS System in individuals age 12 through 17 with partial (focal) onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or mo...

Apr 1st, 2022 - NeuroPace, Inc. is sponsoring a post-approval study (PAS) of the RNS System device. The RNS System is the first FDA-approved closed loop responsive neurostimulator designed to reduce the frequency of seizures in individuals with partial onset seiz...

Jan 4th, 2022 - The object of this study is to assess the efficacy and safety of zonisamide as adjunctive therapy in patients with uncontrolled partial epilepsy. Subject takes zonisamide for 16 weeks (4 weeks-titration period, 8 weeks maintenance period). Dose ra...

May 19th, 2021 - The study was designed to include 3 parts; only the first part is described in this report. Part I of the study was an international, randomized, placebo-controlled, double-blind, parallel group, multicenter clinical study conducted in 19 countrie...

Nov 26th, 2019 - A seizure or convulsion is a paroxysmal, time-limited change in motor activity and/or behavior that results from abnormal electrical activity in the brain . The International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy...

Nov 10th, 2021 - Attention should be paid to changing a tolerated medication to another within its class. Many drugs approved by the US Food and Drug Administration (FDA), have equivalent therapeutic properties as existing drugs.

Jan 16th, 2019 - The US Food and Drug Administration (FDA) has approved the first generic version of the antiseizure medication Sabril (vigabatrin, Lundbeck). Generic vigabatrin (500-mg tablets), made by Teva Pharmaceuticals USA, is indicated as add-on therapy for...

Jul 5th, 2018 - LOS ANGELES—Adjunctive treatment with an investigational antiepileptic drug (AED) reduces the median frequency of partial-onset seizures, according to trial results presented at the 70th Annual Meeting of the American Academy of Neurology. “The re.

Dec 12th, 2017 - WASHINGTON, DC — A microinfusion device that continuously delivers valproate directly to the brain is safe and effective in patients with refractory focal epilepsy, early research shows. Delivery of valproate through the intracerebroventricular de...

Jul 21st, 2017 - What is Epilepsy? Epilepsy is a condition characterized by recurrent and unpredictable seizures. Seizures are characterized by groups of neurons being activated simultaneously, leading to both outward symptoms like muscle jerking and convulsions, ...